Saiid Zarrabian has served as our Head of Strategic Partnerships since November 8, 2021 and as a director since July 7, 2017. He previously served as our President and Chief Executive Officer. Since October 2016, Mr. Zarrabian has served as an advisor to Redline Capital Partners, S.A., a Luxembourg based investment firm. From 2012 to 2014 he served as Chairman and member of the Board of La Jolla Pharmaceutical Company during which time the company transitioned from an OTC listed company to a NASDAQ listed company. From 2012 to 2013 he served as President of the Protein Production Division of Intrexon Corporation, a synthetic biology company. He has also previously served as CEO and member of the Board of Cyntellect, Inc., a stem cell processing and visualization Instrumentation company until its sale in 2012, as President and COO of Senomyx, Inc., a company focused on discovery and commercialization of new flavor ingredients, and as COO of Pharmacopeia, Inc., a former publicly-traded provider of combinatorial chemistry discovery services and compounds, where he also served as President & COO of its MSI Division. In addition, Mr. Zarrabian has served on numerous private and public company boards, including at Immune Therapeutics, Inc., Exemplar Pharma, LLC, Ambit Biosciences Corporation, eMolecules, Inc., and Penwest Pharmaceuticals CO. His other experience includes COO at Molecular Simulations, COO of Symbolics, Inc., and as R&D Director at Computervision, Inc.
How do I contact Saiid Zarrabian?
Has Saiid Zarrabian been buying or selling shares of Kura Oncology?
Saiid Zarrabian has not been actively trading shares of Kura Oncology during the last ninety days. Most recently, on Monday, December 6th, Saiid Zarrabian bought 339 shares of Kura Oncology stock. The stock was acquired at an average cost of $20.65 per share, with a total value of $7,000.35. Learn More on Saiid Zarrabian's trading history.
Who are Kura Oncology's active insiders?
Are insiders buying or selling shares of Kura Oncology?
In the last twelve months, insiders at the sold shares 6 times. They sold a total of 100,060 shares worth more than $2,012,768.59. The most recent insider tranaction occured on November, 18th when COO Kathleen Ford sold 526 shares worth more than $8,431.78. Insiders at Kura Oncology own 5.5% of the company.
Learn More about insider trades at Kura Oncology. Information on this page was last updated on 11/18/2024.
